SEC Company Response from Stoke Therapeutics, Inc. (STOK) (CIK 0001623526) (STOK) — Jun 14, 2019
Stoke Therapeutics, Inc. (STOK) (CIK 0001623526)
Date: June 14, 2019 · CIK: 0001623526 · Accession: 0001193125-19-173266
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-231700
Letter
Re: Stoke Therapeutics, Inc.
June 14, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Registration Statement on Form S-1 (File No. 333-231700)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters (the “Underwriters”), hereby join in the request of Stoke Therapeutics, Inc. with respect to the effective time of the above-referenced Registration Statement so that it will become effective June 18, 2019, at 4:00 p.m. Eastern Time, or as soon thereafter as practicable.
In connection with this acceleration request and pursuant to Rule 460 under the Act, please be advised that, during the period from June 7, 2019 to the date of this letter, we have effected the distribution of approximately 1,636 copies of the preliminary prospectus, dated June 7, 2019, to prospective underwriters, dealers, institutions, and others.
We were advised on June 7, 2019 by the Corporate Financing Department of the Financial Industry Regulatory Authority that it has reviewed the above-captioned proposed offering and that it has determined to raise no objections with respect to the fairness of the terms and arrangements of the offering.
We, the undersigned, as representatives of the several Underwriters, have complied and will comply, and we have been informed by the participating Underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Remainder of Page Intentionally Left Blank]
Very truly yours,
J.P. MORGAN SECURITIES LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP June 14, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Stoke Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-231700) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters (the “Underwriters”), hereby join in the request of Stoke Therapeutics, Inc. with respect to the effective time of the above-referenced Registration Statement so that it will become effective June 18, 2019, at 4:00 p.m. Eastern Time, or as soon thereafter as practicable. In connection with this acceleration request and pursuant to Rule 460 under the Act, please be advised that, during the period from June 7, 2019 to the date of this letter, we have effected the distribution of approximately 1,636 copies of the preliminary prospectus, dated June 7, 2019, to prospective underwriters, dealers, institutions, and others. We were advised on June 7, 2019 by the Corporate Financing Department of the Financial Industry Regulatory Authority that it has reviewed the above-captioned proposed offering and that it has determined to raise no objections with respect to the fairness of the terms and arrangements of the offering. We, the undersigned, as representatives of the several Underwriters, have complied and will comply, and we have been informed by the participating Underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. [Remainder of Page Intentionally Left Blank] Very truly yours, J.P. MORGAN SECURITIES LLC COWEN AND COMPANY, LLC CREDIT SUISSE SECURITIES (USA) LLC on behalf of themselves and as representatives of the Underwriters J.P. MORGAN SECURITIES LLC By: /s/ John Whittaker Name: John Whittaker Title: Managing Director COWEN AND COMPANY, LLC By: /s/ Jason Fenton Name: Jason Fenton Title: Managing Director CREDIT SUISSE SECURITIES (USA) LLC By: /s/ Connie Chiang Name: Connie Chiang Title: Managing Director [Signature Page to Underwriters’ Acceleration Request Letter]